Sathish H.S. Kumar

Dr. Sathish H.S. Kumar

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2017 in Nature
Verified
Journal Article
Open access
PDF file
CVCarmen Venegas
Carmen Venegas
SKSathish H.S. Kumar
Sathish H.S. Kumar
BFBernardo S. Franklin
Bernardo S. Franklin
TDTobias Dierkes
Tobias Dierkes
RBRebecca Brinkschulte
Rebecca Brinkschulte
MHMichael T. Heneka
Michael T. Heneka
The spreading of pathology within and between brain areas is a hallmark of neurodegenerative disorders. In patients with Alzheimer’s disease, deposition of amyloid-β is accompanied by activation of the innate immune system and involves inflammasome-dependent formation of ASC specks in microglia. ASC specks released by microglia bind rapidly to amyloid-β and increase the formation of amyloid-β oligomers and aggregates, acting as an inflammation-driven cross-seed for amyloid-β pathology. Here we show that intrahippocampal injection of ASC specks resulted in spreading of amyloid-β pathology in transgenic double-mutant APPSwePSEN1dE9 mice. By contrast, homogenates from brains of APPSwePSEN1dE9 mice failed to induce seeding and spreading of amyloid-β pathology in ASC-deficient APPSwePSEN1dE9 mice. Moreover, co-application of an anti-ASC antibody blocked the increase in amyloid-β pathology in APPSwePSEN1dE9 mice. These findings support the concept that inflammasome activation is connected to seeding and spreading of amyloid-β pathology in patients with Alzheimer’s disease.

1 September 2011 in Neuron
Verified
Journal Article
Closed access
MKMarkus P. Kummer
Markus P. Kummer
MHMichael Hermes
Michael Hermes
ADAndrea Delekarte
Andrea Delekarte
THThea Hammerschmidt
Thea Hammerschmidt
SKSathish H.S. Kumar
Sathish H.S. Kumar
MHMichael T. Heneka
Michael T. Heneka

1 November 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ITIrfan Y. Tamboli
Irfan Y. Tamboli
EBEsther Barth
Esther Barth
LCLeonie Christian
Leonie Christian
MSMartin Siepmann
Martin Siepmann
SKSathish H.S. Kumar
Sathish H.S. Kumar
Jochen WalterJochen Walter
Jochen Walter
Epidemiological studies indicate that intake of statins decrease the risk of developing Alzheimer disease. Cellular and in vivo studies suggested that statins might decrease the generation of the amyloid β-peptide (Aβ) from the β-amyloid precursor protein. Here, we show that statins potently stimulate the degradation of extracellular Aβ by microglia. The statin-dependent clearance of extracellular Aβ is mainly exerted by insulin-degrading enzyme (IDE) that is secreted in a nonconventional pathway in association with exosomes. Stimulated IDE secretion and Aβ degradation were also observed in blood of mice upon peripheral treatment with lovastatin. Importantly, increased IDE secretion upon lovastatin treatment was dependent on protein isoprenylation and up-regulation of exosome secretion by fusion of multivesicular bodies with the plasma membrane. These data demonstrate a novel pathway for the nonconventional secretion of IDE via exosomes. The modulation of this pathway could provide a new strategy to enhance the extracellular clearance of Aβ.

28 April 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SKSathish H.S. Kumar
Sathish H.S. Kumar
NRNasrollah Rezaei-Ghaleh
Nasrollah Rezaei-Ghaleh
DTDick Terwel
Dick Terwel
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
MRMélisande Richard
Mélisande Richard
Jochen WalterJochen Walter
Jochen Walter
Alzheimer's disease (AD) is the most common form of dementia and associated with progressive deposition of amyloid β‐peptides (Aβ) in the brain. Aβ derives by sequential proteolytic processing of the amyloid precursor protein by β‐ and γ‐secretases. Rare mutations that lead to amino‐acid substitutions within or close to the Aβ domain promote the formation of neurotoxic Aβ assemblies and can cause early‐onset AD. However, mechanisms that increase the aggregation of wild‐type Aβ and cause the much more common sporadic forms of AD are largely unknown. Here, we show that extracellular Aβ undergoes phosphorylation by protein kinases at the cell surface and in cerebrospinal fluid of the human brain. Phosphorylation of serine residue 8 promotes formation of oligomeric Aβ assemblies that represent nuclei for fibrillization. Phosphorylated Aβ was detected in the brains of transgenic mice and human AD brains and showed increased toxicity in Drosophila models as compared with non‐phosphorylated Aβ. Phosphorylation of Aβ could represent an important molecular mechanism in the pathogenesis of the most common sporadic form of AD.

10 February 2014 in Brain
Verified
Journal Article
Open access
PDF file
AUAjeet Rijal Upadhaya
Ajeet Rijal Upadhaya
IKIrina Kosterin
Irina Kosterin
SKSathish H.S. Kumar
Sathish H.S. Kumar
CAChristine A. F. von Arnim
Christine A. F. von Arnim
HYHaruyasu Yamaguchi
Haruyasu Yamaguchi
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
Alzheimer’s disease is characterized by the deposition of amyloid-β peptide in the brain. N-terminal truncation resulting in the formation of AβN3pE and phosphorylation at serine 8 have been reported to modify aggregation properties of amyloid-β. Biochemically, soluble, dispersible, membrane-associated, and insoluble, plaque-associated amyloid-β aggregates have been distinguished. Soluble and dispersible amyloid-β aggregates are both in mixture with the extracellular or intracellular fluid but dispersible aggregates can be cleared from proteins in solution by ultracentrifugation. To clarify the role of phosphorylated amyloid-β and AβN3pE in soluble, dispersible, membrane-associated, and plaque-associated amyloid-β aggregates in the pathogenesis of Alzheimer’s disease we studied brains from 21 cases with symptomatic Alzheimer’s disease, 33 pathologically preclinical Alzheimer’s disease cases, and 20 control cases. Western blot analysis showed that soluble, dispersible, membrane-associated and plaque-associated amyloid-β aggregates in the earliest preclinical stage of Alzheimer’s disease did not exhibit detectable amounts of AβN3pE and phosphorylated amyloid-β. This stage was referred to as biochemical stage 1 of amyloid-β aggregation and accumulation. In biochemical amyloid-β stage 2, AβN3pE was additionally found whereas phosphorylated amyloid-β was restricted to biochemical amyloid-β stage 3, the last stage of amyloid-β aggregation. Phosphorylated amyloid-β was seen in the dispersible, membrane-associated, and plaque-associated fraction. All cases with symptomatic Alzheimer’s disease in our sample fulfilled biochemical amyloid-β stage 3 criteria, i.e. detection of phosphorylated amyloid-β. Most, but not all, cases with pathologically preclinical Alzheimer’s disease had biochemical amyloid-β stages 1 or 2. Immunohistochemistry confirmed the hierarchical occurrence of amyloid-β, AβN3pE, and phosphorylated amyloid-β in amyloid plaques. Phosphorylated amyloid-β containing plaques were, thereby, seen in all symptomatic cases with Alzheimer’s disease but only in a few non-demented control subjects. The biochemical amyloid-β stages correlated with the expansion of amyloid-β plaque deposition and with that of neurofibrillary tangle pathology. Taken together, we demonstrate that AβN3pE and phosphorylated amyloid-β are not only detectable in plaques, but also in soluble and dispersible amyloid-β aggregates outside of plaques. They occur in a hierarchical sequence that allows the distinction of three stages. In light of our findings, it is tempting to speculate that this hierarchical, biochemical sequence of amyloid-β aggregation and accumulation is related to disease progression and may be relevant for an increasing toxicity of amyloid-β aggregates.

1 January 2004 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
SKSathish H.S. Kumar
Sathish H.S. Kumar
Christoph WittmannChristoph Wittmann
Christoph Wittmann
EHElmar Heinzle
Elmar Heinzle